In the latest session, Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $76.87 up 5.97% from its previous closing price of $72.54. In other words, the price has increased by $+4.33 from its previous closing price. On the day, 1231290 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Axsome Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.52 and its Current Ratio is at 3.63. In the meantime, Its Debt-to-Equity ratio is 0.98 whereas as Long-Term Debt/Eq ratio is at 0.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on Mar-20-24, initiated with a Outperform rating and assigned the stock a target price of $108.
On February 06, 2024, UBS started tracking the stock assigning a Buy rating and target price of $111.
On January 25, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $126.RBC Capital Mkts initiated its Outperform rating on January 25, 2024, with a $126 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 15 ’24 when JEFFS ROGER sold 2,347 shares for $71.61 per share. The transaction valued at 168,062 led to the insider holds 120,756 shares of the business.
JEFFS ROGER sold 29,976 shares of AXSM for $2,089,387 on Mar 14 ’24. The Director now owns 120,756 shares after completing the transaction at $69.70 per share. On Sep 15 ’23, another insider, Coleman Mark, who serves as the Director of the company, sold 18,572 shares for $75.18 each. As a result, the insider received 1,396,189 and left with 403,856 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 3.44B and an Enterprise Value of 3.24B. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.46 while its Price-to-Book (P/B) ratio in mrq is 19.06. Its current Enterprise Value per Revenue stands at 11.97 whereas that against EBITDA is -14.39.
Stock Price History:
Over the past 52 weeks, AXSM has reached a high of $98.40, while it has fallen to a 52-week low of $55.02. The 50-Day Moving Average of the stock is 84.98, while the 200-Day Moving Average is calculated to be 75.39.
Shares Statistics:
For the past three months, AXSM has traded an average of 757.59K shares per day and 1.03M over the past ten days. A total of 47.35M shares are outstanding, with a floating share count of 38.78M. Insiders hold about 18.14% of the company’s shares, while institutions hold 80.88% stake in the company. Shares short for AXSM as of Feb 29, 2024 were 7.47M with a Short Ratio of 9.86, compared to 7.49M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.77% and a Short% of Float of 18.98%.
Earnings Estimates
There are 11 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.21 for the current quarter, with a high estimate of -$0.99 and a low estimate of -$1.39, while EPS last year was -$0.26. The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.7 and low estimates of -$1.24.
Analysts are recommending an EPS of between -$1.85 and -$4.91 for the fiscal current year, implying an average EPS of -$3.8. EPS for the following year is $1.14, with 11 analysts recommending between $4.9 and -$2.51.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $73.71M this quarter.It ranges from a high estimate of $79.85M to a low estimate of $65.7M. As of the current estimate, Axsome Therapeutics Inc’s year-ago sales were $26.07M, an estimated increase of 182.70% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $88.25M, an increase of 115.60% less than the figure of $182.70% in the same quarter last year. There is a high estimate of $97.5M for the next quarter, whereas the lowest estimate is $80.6M.
A total of 15 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $450.08M, while the lowest revenue estimate was $339.58M, resulting in an average revenue estimate of $380.17M. In the same quarter a year ago, actual revenue was $270.6M, up 40.50% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $703.12M in the next fiscal year. The high estimate is $942.55M and the low estimate is $538.95M. The average revenue growth estimate for next year is up 84.90% from the average revenue estimate for this year.
